; medical management A group health plan shall not impose any utilization control policies or procedures (as defined by the Secretary), including prior authorization requirements, with respect to opioid overdose reversal agents covered under the plan. Such a plan may apply medical management practices in providing the benefits described in subsection (a). (c) Definition In this section, the term opioid overdose reversal agent means a drug or biological product approved by the Food and Drug Administration for one of the following uses (or a similar use): (1) Complete or partial reversal of opioid depression, including respiratory depression, induced by opioids. (2) Emergency treatment of a known or suspected opioid overdose, as manifested by respiratory or central nervous system depression. . (B) Clerical amendment The table of sections for subchapter B of chapter 100 of the Internal Revenue Code of 1986 is amended by adding at the end the following new item: Sec. 9826. Limitations on cost-sharing for opioid overdose reversal agents. . (4) Effective date The amendments made by this subsection shall apply to plan years beginning on or after January 1, 2025. (b) Safe harbor for absence of deductible for opioid overdose reversal agents (1) In general Paragraph (2) of section 223(c) of the Internal Revenue Code of 1986 is amended by adding at the end the following new subparagraph: (H) Safe harbor for absence of deductible for opioid overdose reversal agents A plan shall not fail to be treated as a high deductible health plan by reason of failing to have a deductible for opioid overdose reversal agents (as defined in section 9826(c)). . (2) Effective date The amendment made by this section shall apply to plan years beginning on or after January 1, 2025. (c) Limitations on cost-Sharing under Medicare part D (1) In general Section 1860D–2 of the Social Security Act ( 42 U.S.C. 1395w–102 ) is amended— (A) in subsection (b)— (i) in paragraph (1)(A), in the matter preceding clause (i), by striking and (9) and inserting ,